Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
Provided By GlobeNewswire
Last update: May 22, 2024
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –
– Presentations highlight Avadel’s continued commitment to address gaps in narcolepsy care –
Read more at globenewswire.com
